Asthma Allergy Immunology

Asthma Allergy Immunology

2022, Vol 20, Num, 2     (Pages: 081-086)

Mepolizumab-Related Adverse Events in Severe Eosinophilic Asthma: A Real-Life Study

Sakine NAZİK BAHÇECİOĞLU 1-2, Murat TÜRK 3, Emel ATAYIK 4, Gülden PAÇACI ÇETİN 1, Bahar ARSLAN 1, İnci GÜLMEZ 5, İnsu YILMAZ 1,

1 Department of Chest Diseases, Division of Allergy and Clinical Immunology, Erciyes University School of Medicine, Kayseri, Turkey
2 Department of Immunology and Allergy, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey
3 Department of Chest Diseases, Division of Allergy and Clinical Immunology, Kayseri City Hospital, Kayseri, Turkey
4 Department of Chest Diseases, Division of Allergy and Clinical Immunology, Konya City Hospital, Konya, Turkey
5 Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey

DOI: 10.21911/aai.662
Viewed: 365
 - 
Downloaded : 198

Objective: Mepolizumab, an anti-interleukin 5 humanized monoclonal antibody, which is listed among the treatment options in the Global Initiative for Asthma 2020, is recommended as a step 5 therapy option for patients with uncontrolled severe eosinophilic asthma. Real-life data on adverse drug reactions of mepolizumab are limited. We aimed to analyze the safety profile of mepolizumab retrospectively among patients who were treated with mepolizumab with the diagnosis of eosinophilic severe asthma.

Materials and Methods: Severe eosinophilic asthma patients from two different centers who were treated with mepolizumab between June 2018 and July 2020 were analyzed retrospectively. The data of the mepolizumab-related adverse event forms, which were filled out at each visit, were retrospectively evaluated.

Results: Eighty three patients were included in the study. The most commonly reported adverse events which could be related to mepolizumab were myalgia/arthralgia, headache, and local injection site reactions. Nevertheless, none of these required the discontinuation of the drug. Mepolizumab-related adverse events that required discontinuation of mepolizumab treatment were observed in two (2.4%) cases but their association with the drug could not be clearly defined. Anaphylaxis or herpes infection was not detected in any of the cases.

Conclusion: These outcomes reveal that mepolizumab is a well-tolerated drug in real-life. However, further large-scale real-life studies with long-term follow-up are still needed.

Keywords : Mepolizumab, mepolizumab adverse events, severe asthma treatment, adverse events, mepolizumab treatment